← Leaderboards
Anderson Wayne
Okava Pharmaceuticals, Inc.
$499,280
Attributed
$499,280
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249.7K · FY2020–21$250K$187.5K$125K$62.5K$0
'20
'21
Funding mix
By agency
FDA$499,280 · 1
By mechanism
R01$499,280 · 1
Top collaborators
No co-investigators on record.
Grant awards (2)
A Reasonable Expectation of Effectiveness Clinical Trial of OKV-1001 for the Treatment of Primary (Non-Associative) Immune-Mediated Hemolytic Anemia in Dogs$249,623
R01 · FY2021 · FD · contact PI
A Reasonable Expectation of Effectiveness Clinical Trial of OKV-1001 for the Treatment of Primary (Non-Associative) Immune-Mediated Hemolytic Anemia in Dogs$249,657
R01 · FY2020 · FD · contact PI